FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947173600> ?p ?o ?g. }

• W2947173600 abstract "e18365 Background: Real-world evidence is lacking regarding costs for FDA-approved/NCCN Category 1 treatments for patients with metastatic pancreatic cancer (m-PANC). We analyzed costs by service in the Medicare fee-for-service (FFS) population by chemotherapy regimen and line of therapy (LOT). Methods: Patients with m-PANC were identified using ICD-9/10 diagnosis codes in the 2013-2017 Medicare 100% Limited Data Set claims, which include all Medicare paid FFS claims, except professional services, for 45 million Medicare FFS beneficiaries. We studied mean monthly costs by service category, regimen, and LOT. Patients in our study had two or more claims with a pancreatic cancer (PANC) diagnosis more than 30 days apart and one or more claims with a secondary malignancy (metastasis) diagnosis on or after the first PANC diagnosis date. We defined index date as the earliest metastasis diagnosis date. We excluded patients with pre-index non-PANC malignancies and those without 6 months pre-index and 3 months (or until death, if earlier) post-index Medicare FFS enrollment. LOTs were assigned based on therapies used. LOTs ended the day before a new chemotherapy began, 28 days after the last chemotherapy (if no new chemotherapy), or upon death. We analyzed the FDA-approved/NCCN Category 1 treatments used most commonly in first line (1L): gemcitabine monotherapy, gemcitabine/nab-paclitaxel, and FOLFIRINOX; and in second or third line (2L, 3L): liposomal irinotecan. Results: Mean monthly Parts A and B (excluding professional) costs for 1L gemcitabine monotherapy were lower than gemcitabine/nab-paclitaxel or FOLFIRINOX ($5,267, $9,116, and $8,046, respectively). Part B drug costs other than chemotherapy were higher for FOLFIRINOX than gemcitabine/nab-paclitaxel or gemcitabine monotherapy ($3,881, $1,155, and $827, respectively). Inpatient services were similar across 1L regimens ($2,721-$3,303). Despite disease progression, mean monthly 2L and 3L costs for liposomal irinotecan were $10,809 and $12,225, respectively. Part B drugs other than chemotherapy ($2,133-$2,509) were comparable to 1L regimens, but inpatient services ($2,306-$2,405) were lower. Conclusions: The mean monthly cost increased by LOT for m-PANC FDA-approved/NCCN category 1 regimens. Interestingly, Part A inpatient costs decreased in 2L and 3L, while Part B drug costs other than chemotherapy were comparable." @default.
• W2947173600 created "2019-06-07" @default.
• W2947173600 creator A5009391815 @default.
• W2947173600 creator A5037797854 @default.
• W2947173600 creator A5075996783 @default.
• W2947173600 creator A5083445481 @default.
• W2947173600 date "2019-05-20" @default.
• W2947173600 modified "2023-09-23" @default.
• W2947173600 title "Monthly parts a and b costs by service and line of therapy for FDA-approved/NCCN category 1 treatments for patients with metastatic pancreatic cancer." @default.
• W2947173600 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e18365" @default.
• W2947173600 hasPublicationYear "2019" @default.
• W2947173600 type Work @default.
• W2947173600 sameAs 2947173600 @default.
• W2947173600 citedByCount "0" @default.
• W2947173600 crossrefType "journal-article" @default.
• W2947173600 hasAuthorship W2947173600A5009391815 @default.
• W2947173600 hasAuthorship W2947173600A5037797854 @default.
• W2947173600 hasAuthorship W2947173600A5075996783 @default.
• W2947173600 hasAuthorship W2947173600A5083445481 @default.
• W2947173600 hasConcept C121608353 @default.
• W2947173600 hasConcept C126322002 @default.
• W2947173600 hasConcept C141071460 @default.
• W2947173600 hasConcept C143998085 @default.
• W2947173600 hasConcept C2780210213 @default.
• W2947173600 hasConcept C71924100 @default.
• W2947173600 hasConceptScore W2947173600C121608353 @default.
• W2947173600 hasConceptScore W2947173600C126322002 @default.
• W2947173600 hasConceptScore W2947173600C141071460 @default.
• W2947173600 hasConceptScore W2947173600C143998085 @default.
• W2947173600 hasConceptScore W2947173600C2780210213 @default.
• W2947173600 hasConceptScore W2947173600C71924100 @default.
• W2947173600 hasLocation W29471736001 @default.
• W2947173600 hasOpenAccess W2947173600 @default.
• W2947173600 hasPrimaryLocation W29471736001 @default.
• W2947173600 hasRelatedWork W2120120139 @default.
• W2947173600 hasRelatedWork W2156052776 @default.
• W2947173600 hasRelatedWork W2278263526 @default.
• W2947173600 hasRelatedWork W2279582904 @default.
• W2947173600 hasRelatedWork W2513824832 @default.
• W2947173600 hasRelatedWork W2548615588 @default.
• W2947173600 hasRelatedWork W2590581923 @default.
• W2947173600 hasRelatedWork W2591137545 @default.
• W2947173600 hasRelatedWork W2604915010 @default.
• W2947173600 hasRelatedWork W2921837178 @default.
• W2947173600 hasRelatedWork W2982510629 @default.
• W2947173600 hasRelatedWork W3005296012 @default.
• W2947173600 hasRelatedWork W3014751745 @default.
• W2947173600 hasRelatedWork W3031823864 @default.
• W2947173600 hasRelatedWork W3042734248 @default.
• W2947173600 hasRelatedWork W3093476204 @default.
• W2947173600 hasRelatedWork W3111498065 @default.
• W2947173600 hasRelatedWork W3132423864 @default.
• W2947173600 hasRelatedWork W3178091993 @default.
• W2947173600 hasRelatedWork W3200905314 @default.
• W2947173600 isParatext "false" @default.
• W2947173600 isRetracted "false" @default.
• W2947173600 magId "2947173600" @default.
• W2947173600 workType "article" @default.